Gossamer Bio, Inc.
Financials
Valuation Metrics
Gossamer Bio, Inc.'s Market Cap is $57M. At end of 2025 it was $56.20B. Ranked #3078 of 3,118 in US market (top 99%), #1439 of 1,474 on NASDAQ (top 98%), #262 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $57M | US#3,078/3,118 Sec#262/265 |
| Revenue | $53M | US#2,738/3,118 Sec#146/265 |
| Net Income | $-125M | US—/3,118 Sec—/265 |
| Total Assets | $77M | US#3,061/3,118 Sec#261/265 |
| Net Assets | $-94M | US#2,953/3,118 Sec#249/265 |
| Employees | 162 | US#2,517/3,118 Sec#138/265 |
| Value | ||
| P/S | 1.07x | US#839/3,118 Sec#15/265 |
| FCF Yield | -284.64% | US—/3,118 Sec—/265 |
| Profitability | ||
| Op. Margin | -311.70% | US#2,760/3,118 Sec#143/265 |
| Revenue Growth | 32.43% | US#385/3,118 Sec#60/265 |
| Financial Health | ||
| Total Debt | $39M | US#2,637/3,118 Sec#163/265 |
| FCF | $-163M | US#2,733/3,118 Sec#191/265 |
| Cash | $41M | US#2,648/3,118 Sec#235/265 |
| Current Ratio | 0.53x | US#2,693/3,118 Sec#265/265 |
| Performance | ||
| 1Y Return | -95.23% | US#3,124/3,118 Sec#264/265 |
| 1M Return | -12.70% | US#2,584/3,118 Sec#193/265 |
| From 52W High | -96.98% | US#3,126/3,118 Sec#264/265 |
| 1Y MDD | -97.22% | US#3,125/3,118 Sec#264/265 |
| Trading | ||
| Volume | 182,630 shares | US#2,713/3,118 Sec#252/265 |
| Trading Value | $2M | US#2,912/3,118 Sec#246/265 |
| Per Share | ||
| EPS | $-20.49 | US—/3,118 Sec—/265 |
| BPS | $-15.39 | US—/3,118 Sec—/265 |
Company Info
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.